180 related articles for article (PubMed ID: 16899504)
1. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
Nihtyanova SI; Brough GM; Black CM; Denton CP
Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
[TBL] [Abstract][Full Text] [Related]
3. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
6. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
Le EN; Wigley FM; Shah AA; Boin F; Hummers LK
Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
Nambiar AM; Anzueto AR; Peters JI
PLoS One; 2017; 12(4):e0176312. PubMed ID: 28441449
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.
Liossis SN; Bounas A; Andonopoulos AP
Rheumatology (Oxford); 2006 Aug; 45(8):1005-8. PubMed ID: 16490756
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil for the treatment of scleritis.
Sen HN; Suhler EB; Al-Khatib SQ; Djalilian AR; Nussenblatt RB; Buggage RR
Ophthalmology; 2003 Sep; 110(9):1750-5. PubMed ID: 13129873
[TBL] [Abstract][Full Text] [Related]
11. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
Derk CT; Grace E; Shenin M; Naik M; Schulz S; Xiong W
Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
Hardinger KL; Brennan DC; Lowell J; Schnitzler MA
Transpl Int; 2004 Nov; 17(10):609-16. PubMed ID: 15517170
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis.
Murray ML; Cohen JB
Clin Exp Dermatol; 2007 Jan; 32(1):23-7. PubMed ID: 17059445
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus.
Riskalla MM; Somers EC; Fatica RA; McCune WJ
J Rheumatol; 2003 Jul; 30(7):1508-12. PubMed ID: 12858449
[TBL] [Abstract][Full Text] [Related]
16. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
Poelman CL; Hummers LK; Wigley FM; Anderson C; Boin F; Shah AA
J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
[TBL] [Abstract][Full Text] [Related]
20. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
Tierce JC; Porterfield-Baxa J; Petrilla AA; Kilburg A; Ferguson RM
Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
